Prof John Gribben (University London and Barts, London, UK) chairs a discussion for ecancertv at iwCLL 2015 with Prof Michael Hallek (University Clinic of Cologne, Cologne, Germany) Dr Michael Keating (University of Texas MD Anderson Cancer Center, Houston, USA) Prof Kanti Rai (Long Island Jewish Medical Center, New York, USA) about the highlights of iwCLL 2015. They focus on the current and evolving landscape of CLL and potential treatment pathways. They also note the importance of the...

Dr O’Brien talks to ecancertv at the 2015 International Workshop on Chronic Lymphocytic Leukaemia (CLL) about the results of a new phase I study of duvelisib (IPI-145) in patients with relapsed or refractory CLL.

Professor Catovsky speaks to ecancertv at the 2015 International Workshop on Chronic Lymphocytic Leukaemia (CLL) about the long-term outcomes of the fludarabine plus cyclophosphamide in a randomised controlled trial for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial).

Professor Mulligan, President of the 2015 iwCLL Organising Committee, speaks to ecancertv about the highlights of the three day 2015 16th International Workshop on Chronic Lymphocytic Leukaemia (CLL).

Prof Seymour talks to ecancertv at the 2015 16th International Workshop on Chronic Lymphocytic Leukaemia (CLL) about promising new clinical trial results and highlights from conference.

Prof Cymbalista talks to ecancertv at iwCLL 2015 - International Workshop on Chronic Lymphocytic Leukaemia (CLL) about the need for guidelines regarding monitoring of CLL patients on ibrutinib for atrial fibrillation.

Dr Thurgood discusses her research on protein expression variation in CLL with ecancertv at iwCLL 2015 - The 2015 16th International Workshop on Chronic Lymphocytic Leukaemia (CLL).

Associate Professor Wu talks to ecancertv at the 2015 International Workshop on Chronic Lymphocytic Leukaemia (CLL) about the results of her analysis study into CLL mutations.

Associate Professor Wu talks to ecancertv at the 2015 International Workshop on Chronic Lymphocytic Leukaemia (CLL) about her programme of research in CLL.

Dr Giles Best (Royal North Shore Hospital, Sydney, Australia) and Prof Arnon Kater (Academic Medical Center, Amsterdam, The Netherlands) discuss the highlights of the Young Investigators Meeting (YIM) at the International Workshop on Chronic Lymphocytic Leukaemia (CLL) for ecancertv in Sydney, Australia. They also discuss the ways in which this group has evolved and been integrated into the main iwCLL meeting. In particular, they note the importance of the support the group receives from...

Dr Chan talks to ecancertv about the incidence of chronic lymphocytic leukaemia (CLL) in the Hong Kong ethnic Chinese population at the 2015 International Workshop on CLL. The findings of an epidemiological study, which covered around 80% of the Hong Kong population, gave an incidence of CLL of 1-2 per 100,000 per year.

Prof Ghia talks to ecancertv at the 2015 International Workshop on Chronic Lymphocytic Leukaemia (CLL) about the results of crystallographic analysis of the B-cell receptor immunoglobulin in CLL patients assigned to subgroup number four.

Dr Wiestner talks to ecancertv about the incidence of bleeding-related adverse events in chronic lymphocytic leukaemia patients treated with ibrutinib at the 16th International Workshop on CLL. He also discusses his findings on possible risk factors.

Dr Rawstron talks to ecancertv about the importance harmonisation of residual disease monitoring in CLL using flow cytometry at iwCLL 2015 - International Workshop on Chronic Lymphocytic Leukaemia (CLL).

Dr Michallet talks to ecancertv about the primary results from the MABLE study that she presented at iwCLL 2015 16th International Workshop on Chronic Lymphocytic Leukaemia (CLL). The randomised study investigated the efficacy and safety of rituximab plus bendamustine (R-Benda) and rituximab plus chlorambucil (R-Clb) in fludarabine-ineligible patients with CLL.

Professor Carlo Croce speaks to ecancertv at the 2015 International Workshop on Chronic Lymphocytic Leukaemia (CLL) about studies on genetic deletions in the pathogenesis of CLL.

Prof Vajdic discusses results from large-scale epidemiological studies with ecancertv at the 16th International Workshop on Chronic Lymphocytic Leukaemia (CLL). Her research utilises pooled data from the International Lymphoma Epidemiolgoy (Interlymph) Consortium. Prof Vajdic also discusses the future opportunities for big data research in non-Hodgkins lymphoma and CLL.

Assistant Professor Danilov talks to ecancertv at the 2015 International Workshop on Chronic Lymphocytic Leukaemia (CLL) about microenvironment-mediated mechanisms that protect CLL cells from apoptosis. He presents results of in vitro studies using pevonedistat to inhibit the NEDD8-activating enzyme and induce apoptosis.

Prof Coutré speaks to ecancertv about the next generation treatments for CLL; idelalisib and rituximab, at iwCLL 2015 - 16th International Workshop on Chronic Lymphocytic Leukaemia (CLL) held in Sydney, Australia. He also talks about his translational research and the future of CLL treatment and potential benefits to patients.

Prof Stevenson talks to ecancertv about human B-cell receptor structure and function in CLL at iwCLL 2015 - 16th International Workshop on Chronic Lymphocytic Leukaemia (CLL) held in Sydney, Australia. She highlights the two distinct types of immunoglobulin genes and their relationship to prognosis in CLL.

Prof Awan speaks to ecancertv about the results of a Phase Ib trial of voxtalisib (a P13K/MTOR inhibitor) in combination with chemoimmunotherapy in CLL patients at iwCLL 2015 - 16th International Workshop on Chronic Lymphocytic Leukaemia (CLL) held in Sydney, Australia. He highlights disease response rates and adverse events.

Dr Cramer discusses the results of the HELIOS trial including subgroup analysis and safety profile at iwCLL 2015 - International Workshop on Chronic Lymphocytic Leukaemia (CLL) held in Sydney, Australia. The double-blind phase III HELIOS trial randomized 578 previously treated patients with measurable relapsed/refractory CLL/SLL to BR for a maximum of six cycles plus either placebo (n = 289) or 420 mg/day of ibrutinib (n = 289). The full six cycles of BR were completed by 83% and 78% of...

Dr Best discusses his research on CLL cells cultured under hypoxic conditions with ecancertv. The findings presented in Sydney, Australia at the 2015 International Workshop on Chronic Lymphocytic Leukaemia (CLL) demonstrated that IBL-202 inhibited both PIM and PI3-kinase.

Prof Cooper discusses the history of the B-cell in its 50th anniversary year at iwCLL 2015 - 16th International Workshop on Chronic Lymphocytic Leukaemia (CLL). He talks about his research showing that B-lymphocytes and T-lymphocytes have evolved together over the last 500 million years.